For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
This week in health care policy: September 21–25, 2026
Innovation watch FDA approves the first treatment for Sanfilippo syndrome. On September 17, the FDA approved Ultragenyx’s Fayuvi, a one-time…
Blog
How The No Surprises Act worsened the problem of surprise bills
Next week, Sen. Bill Cassidy (R-LA) will convene a roundtable to discuss adjustments to the 2020 No Surprises Act, which has come under…
National Review
Prescription Drugs Save Lives at a (Mostly) Reasonable Cost
Prescription drugs are an extraordinary lifesaving and life-enhancing technology, so integrated into our daily lives that, nowadays, we perhaps take them for granted. Headlines and…
Search Posts
Fox News
Pelosi, Progressive Caucus Clash over Drug Pricing Legislation
Fox News cites Research Fellow Patrick Hedger on Nancy Pelosi’s proposed “Lower Drug Costs Now Act.” But according to the right-leaning Competitive Enterprise…
Townhall
The Black Market Is the Real Problem with Vaping
Townhall cites Senior Fellow Michelle Minton on e-cigarettes and the black market. But, as Michelle Minton of the Competitive Enterprise Institute stated after…
News Release
House Bill Setting Price Controls on Medicines Would Endanger Patients, Harm Innovation
House Speaker Nancy Pelosi and Majority Leader Steny Hoyer plan to bring H.R. 3, the Lower Drug Costs Now Act, to the floor for a…
Real Clear Markets
With Drug Pricing, Bipartisanship Isn’t an Excuse to Violate the Laws of Economics
In an age of intense political polarization, some may assume anything that House Speaker Nancy Pelosi and President Donald Trump even marginally agree on has…
The Economic Standard
Drug Reference Pricing Threatens Patient Health, Innovation
The Economic Standard cites Research Fellow Patrick Hedger and CEI’s event on drug reference pricing: Some recent proposals to lower drug prices are…
News Release
Foreign Reference Pricing Schemes Threaten Patient Health and America’s Leadership in Medical Innovation
International policy experts and patients gathered today in Washington, D.C. to discuss the potential impact of foreign reference pricing schemes, which have been proposed by the…